Special Issue

Mechanisms and Novel Therapeutic Approaches for Neurodegenerative Diseases

Message from the Guest Editor

Neurodegenerative Diseases are among the main health problems in elderly. These pathologies generate autonomy problems in the affected people, as well as important public health problems and an important cost for the health systems. The mechanisms underlying neurodegeneration are sometimes common to various diseases, and differentiated in other cases. In any case, in many cases the mechanisms are unknown, and in others, despite being known, there are no effective therapies to treat these diseases. In fact, there are few therapies for the treatment of these diseases, and either for preventing, slowing or stopping neurodegeneration. In this Special Issue, we invite our colleagues to send review and original research articles that focus on any aspect of molecular and cellular mechanisms of neurodegeneration, as well as therapeutic approaches. Also manuscripts dealing with related subjects will be appreciated.

Dr. Chandresh Gajera

Guest Editor

Dr. Fernando Cardona

Instituto de Biomedicina de Valencia-CSIC, 46010 Valencia, Spain

Deadline for manuscript submissions

closed (31 August 2024)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/133169

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).